Introduction {#S0001}
============

Nearly 90% of cases of renal artery stenosis (RAS) are associated with atherosclerosis and most commonly involve the origin and the proximal third of the main renal artery. Significant renal artery stenosis is present in up to 5% of hypertensive patients, 4--28% of patients with coronary artery disease undergoing coronary angiography and 40% of patients with peripheral artery disease \[[@CIT0001], [@CIT0002]\]. Atherosclerotic RAS is a progressive disease related to increased mortality and morbidity. However, the optimal treatment of atherosclerotic RAS is controversial. Percutaneous transluminal renal angioplasty with stent (PTRAS) is a safe, durable and effective procedure for the treatment of atherosclerotic RAS but the indications for PTRAS are disputed. The PTRAS is shown to be an effective method for the control of renovascular hypertension, but the success of PTRAS regarding maintenance of renal function in patients with normal or impaired renal function is still controversial \[[@CIT0003]--[@CIT0007]\]. The ASTRAL trial rekindled the debate about the effectiveness of PTRAS \[[@CIT0003]\]. The trial enrolled 806 randomly assigned patients (403 patients in the PTRAS group and 403 patients in the medical therapy group) from 2000 to 2007 to be followed over a 5-year period. Although the baseline characteristics appeared similar, nearly one-half of the patients in both groups had ARAS \< 70%, which created a significant bias against PTRAS. Objective validation of the stenosis degree was also lacking in this study, resulting in overestimation of narrowing. The ASTRAL investigators failed to recognize or acknowledge that there is no clinical equipoise in randomizing mild ARAS lesions to revascularization. Furthermore, the procedural success rate was lower with a high rate of complications. Therefore, the results of the ASTRAL trial study should be carefully evaluated.

Aim {#S0002}
===

The aim of the present study is to evaluate the influence of gender and presence of chronic renal failure on the outcomes of renal artery stenting due to atherosclerosis.

Material and methods {#S0003}
====================

Study population {#S20004}
----------------

One hundred thirty-seven consecutive patients with resistant hypertension (needing at least 3 medications including diuretics and other antihypertensive drugs such as angiotensin receptor blockers, angiotensin-converting-enzyme inhibitors, nitrates, α-blockers, β-blockers and calcium channel blockers) and suspected coronary artery disease underwent diagnostic renal angiography along with coronary angiography due to suspected coronary artery disease. Severe atherosclerotic RAS was defined as luminal narrowing ≥ 70% by renal angiography. Of the 137 patients, severe RAS was detected in 28 patients and treated with PTRAS. These 28 patients were included in this study. Of these 28 patients critical coronary stenosis was detected in 18 patients and these 18 patients were treated with coronary stents. The remaining 10 patients had non-critical stenosis of coronary arteries. Informed consent was obtained from all subjects, and the investigation conforms to the principles outlined in the Declaration of Helsinki. Coronary artery disease risk factors, blood pressures, anti-hypertensive medications, and laboratory and echocardiographic data were recorded.

Definitions {#S20005}
-----------

Unilateral stenosis was defined as unilateral ostial stenosis with no stenosis in the contralateral artery. Bilateral stenosis was defined as ostial stenosis on both sides, unilateral ostial stenosis with contralateral occlusion, or solitary kidney with ostial stenosis. For each patient, coronary artery disease risk factors including diabetes mellitus, smoking and hypercholesterolemia were obtained. Diabetes mellitus was defined as fasting blood glucose \> 126 mg/dl or patients on oral antidiabetic and/or insulin therapy. Hyperlipidemia is accepted as fasting low-density lipoprotein (LDL) cholesterol level \> 160 mg/dl or patients on antihyperlipidemia therapy.

Blood pressure measurements {#S20006}
---------------------------

The blood pressure was measured using a mercury sphygmomanometer with a cuff appropriate to the arm circumference (Korotkoff phase I for systolic blood pressure and V for diastolic blood pressure). Blood pressure measurements were performed twice for each subject in outpatient clinical settings at least 30 min after resting in compliance with the World Health Organization recommendations and their mean was used for statistical analysis.

Laboratory measurements {#S20007}
-----------------------

The laboratory data including blood cell counts, fasting glucose, total cholesterol, LDL, high-density lipoprotein (HDL), urea and creatinine were obtained before coronary angiography. Serum creatinine levels were assessed 6 months after the procedure, again. Estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft-Gault formula \[[@CIT0008]\]. Chronic renal failure was defined as eGFR \< 60 ml/min/1.73 m^2^.

Transthoracic echocardiographic assessment such as ejection fraction % (EF%) was performed in all patients. Renal atrophy was assessed by renal ultrasonography.

Percutaneous technique {#S20008}
----------------------

Renal artery stenting was performed at least one month after coronary angiography and/or percutaneous coronary intervention (range: 1--2 months). Femoral arterial puncture was performed in all patients, and all procedures were performed through a 7 F sheath introducer, with right Judkins or internal mammary artery guiding catheter via a 0.14 mm coronary guide wire. The guide wire was passed through the stenosis and a balloon-expandable bare metal stent was placed over the guide wire. For treatment of ostial stenoses, the stent was positioned so that 1 mm to 2 mm protruded into the aortic lumen, ensuring complete coverage of the aortic plaque. An intervention was considered technically successful if the residual stenosis was \< 30%. Procedural success is defined as the presence of technical success without major complications. Antiplatelet therapy was started at least 1 day before intervention and routinely consisted of 75 mg of clopidogrel daily for 3 months and 100 mg of aspirin indefinitely. Immediately before the intervention, we administered a bolus dose of 5000 IU of heparin. After the procedure the mainstay of the antihypertensive therapy included β-blockers with angiotensin-converting-enzyme inhibitors/angiotensin receptor blockers. In patients with congestive symptoms or blood pressure beyond the targets, diuretics were added.

Statistical analysis {#S20009}
--------------------

Statistical analyses were performed using SPSS version 17.0 for Windows software (SPSS Inc., Chicago, USA). Continuous variables are expressed as mean ± standard deviation (SD) and categorical variables are expressed as percentage. Comparisons of continuous variables were performed using the unpaired Student *t* test, the paired Student *t* test for normally distributed variables, and the Wilcoxon test was used for the analysis of non-normally distributed variables. Categorical variables were compared with the χ^2^ test. Results were evaluated within the 95% confidence interval and *p* \< 0.05 was accepted as significant.

Results {#S0010}
=======

A total of 28 atherosclerotic RAS patients underwent percutaneous transluminal renal angioplasty and 36 renal stents were placed. Procedural success was achieved in all patients (100%). Of the 28 patients, left renal artery stenosis was found in 10 patients (35.7%), right renal artery stenosis in 10 (35.7%), and bilateral renal artery stenosis in 8 (28.6%). Major complications including procedure-related death, cerebrovascular accident, myocardial infarction, arterial rupture, embolism, and acute renal failure were not observed. Two patients had hematoma at the puncture site. The mean duration of hypertension was 17.71 ±11.49 years. Angiotensin-converting-enzyme inhibitors were used by 17.9%, angiotensin receptor blockers by 42.9%, β-blockers by 75.0%, calcium channel blockers by 67.9%, α-blockers by 14.3%, nitrates by 39.3%, centrally acting antihypertensives by 14.3% and diuretics by 100% of patients. None of the patients with bilateral ARAS used angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers. Baseline characteristics including age, presence of diabetes, hyperlipidemia, smoking habit, medications, location of stenosis, stent size and laboratory data were similar between men and women ([Table 1](#T0001){ref-type="table"}). Basal systolic blood pressure levels were similar between men and women but diastolic blood pressure levels were significantly higher among women (*p* = 0.014). Post-PTRAS systolic and diastolic blood pressure levels were similar between men and women. Significant improvement of systolic and diastolic blood pressure control was achieved after PTRAS (153.04 ±17.07 mm Hg vs. 124.75 ±11.40 mm Hg, *p* = 0.001 and 92.50 ±10.76 mm Hg vs. 77.54 ±8.23 mm Hg, *p* \< 0.001, respectively) ([Figure 1](#F0001){ref-type="fig"}). Both men and women showed similar benefit from PTRAS for systolic and diastolic blood pressure regulation ([Table 2](#T0002){ref-type="table"}). Baseline and post-PTRAS creatinine levels were similar for men and women. While basal eGFR was similar between men and women, post-PTRAS eGFR levels were significantly higher in males (*p* = 0.034). Although mean eGFR and creatinine levels did not significantly improve at the 6-month follow-up visit compared to baseline values, of 28 patients 13 (46.4%) patients had improvement of renal functions ([Figure 2](#F0002){ref-type="fig"}). Among patients with improved eGFR, basal eGFR was significantly lower, basal creatinine was significantly higher and hyperlipidemia and chronic renal failure were significantly more common compared to non-responders ([Table 3](#T0003){ref-type="table"}).

![Box plot graph shows pre- and post-PTRAS values of systolic blood pressure (**A**) and diastolic blood pressure (**B**)](PWKI-9-21396-g001){#F0001}

![Box plot graph shows pre- and post-PTRAS values of eGFR (**A**), antihypertensive drug number needed to control blood pressure (**B**)](PWKI-9-21396-g002){#F0002}

###### 

Baseline characteristics of patients

  Variable           Men (*n* = 13)   Women (*n* = 15)   Total (*n* = 28)   Value of *p*
  ------------------ ---------------- ------------------ ------------------ --------------
  Age \[years\]      58.77 ±14.12     67.87 ±14.37       63.64 ±14.73       0.104
  DM, *n* (%)        4 (30.8)         4 (26.7)           8 (28.6)           1.000
  HL, *n* (%)        6 (46.2)         4 (26.7)           10 (35.7)          0.283
  Smoking, *n* (%)   6 (46.2)         2 (13.3)           8 (28.6)           0.096
  PreDN              3.85 ±0.80       3.60 ±0.91         3.71 ±0.85         0.458
  PostDN             2.31 ±0.75       2.60 ±0.63         2.46 ±0.69         0.274
  DL, *n* (%)        11 (84.6)        13 (86.7)          24 (85.7)          0.877
  EF \[%\]           62.31 ±4.84      61.00 ±4.71        61.61 ±4.72        0.476
  SL \[mm\]          17.27 ±2.19      16.69 ±2.84        16.97 ±2.32        0.551
  SD \[mm\]          6.20 ±0.56       6.00 ±0.82         6.08 ±0.74         0.452
  CAD, *n* (%)       9 (69.2)         11 (73.3)          20 (71.4)          0.811
  PAH, *n* (%)       2 (15.4)         1 (6.7)            3 (10.7)           0.583
  RA, *n* (%)        2 (15.4)         4 (26.7)           6 (21.4)           0.655
  WBC                9.09 ±2.43       8.01 ±3.05         8.51 ±2.78         0.313
  Hemoglobin         11.91 ±1.68      11.62 ±1.75        11.75 ±1.69        0.662
  Ure                49.46 ±20.22     48.06 ±26.58       48.71 ±23.42       0.878
  CRF, *n* (%)       7 (53.8)         9 (60.0)           16 (57.1)          0.743
  IeGFR, *n* (%)     6 (46.2)         7 (46.7)           13 (46.4)          0.978
  Total C            186.31 ±46.25    205.47 ±46.62      196.57 ±40.61      0.286
  LDL                120.08 ±38.99    131.13 ±42.75      126.00 ±40.68      0.484
  HDL                37.02 ±10.33     46.22 ±12.68       41.95 ±12.36       0.047

DM -- diabetes mellitus, HL -- hyperlipidemia, PreDN -- preprocedural drug number, PostDN -- postprocedural drug number, DL -- medication dosage lowering, EF -- left ventricle ejection fraction, SL -- stent length, SD -- stent diameter, CAD -- significant coronary artery disease, PAH -- peripheral artery disease, RA -- renal atrophy, WBC -- white blood cell count, CRF -- chronic renal failure, IeGFR -- improved estimated glomerular filtration rate, Total C -- total cholesterol, LDL -- low-density lipoprotein, HDL -- high-density lipoprotein

###### 

Pre-percutaneous transluminal renal angioplasty with stent (PTRAS) and at 6-month follow-up results of blood pressure, medications, creatinine and estimated glomerular filtration rate

  Variable          Pre-PTRAS       Post-PTRAS      Value of *p*
  ----------------- --------------- --------------- --------------
  SP                153.04 ±17.07   124.75 ±11.40   \< 0.001
  Men               146.92 ±15.88   124.08 ±9.00    \< 0.001
  Women             158.33 ±16.76   125.33 ±13.43   \< 0.001
  DP                92.50 ±10.76    77.54 ±8.23     \< 0.001
  Men               87.31 ±8.81     76.31 ±7.93     0.001
  Women             97.00 ±10.49    78.60 ±8.60     \< 0.001
  Number of drugs   3.71 ±0.85      2.46 ±0.69      \< 0.001
  Men               3.85 ±0.80      2.31 ±0.75      \< 0.001
  Women             3.60 ±0.91      2.60 ±0.63      0.006
  Creatinine        1.13 ±0.31      1.13 ±0.31      0.150
  Men               1.41 ±0.53      1.17 ±0.32      0.088
  Women             1.15 ±0.42      1.10 ±0.30      0.767
  eGFR              60.89 ±35.21    61.75 ±21.08    0.899
  Men               62.77 ±31.31    70.69 ±22.94    0.300
  Women             59.27 ±39.30    54.00 ±16.37    0.632

PTRAS -- percutaneous transluminal renal artery stenting, SP -- systolic blood pressure, DP -- diastolic blood pressure, eGFR -- estimated glomerular filtration rate

###### 

Characteristics of patients with increased and decreased estimated glomerular filtration rate

  Variable        IeGFR (*n* = 13)   DeGFR (*n* = 15)   Value of *p*
  --------------- ------------------ ------------------ --------------
  Pre-DN          3.77 ±0.93         3.67 ±0.82         0.758
  Post-DN         2.54 ±0.78         2.40 ±0.63         0.607
  SP              147.69 ±14.52      157.67 ±18.21      0.125
  DP              89.62 ±9.23        95.00 ±11.65       0.192
  EF              60.92 ±4.77        62.20 ±4.77        0.486
  WBC             8.98 ±2.96         8.10 ±2.66         0.415
  HB              11.10 ±1.54        12.32 ±1.66        0.055
  eGFR1           36.77 ±7.70        81.80 ±36.49       \< 0.001
  Creatinine      1.66 ±0.35         0.92 ±0.26         \< 0.001
  LDL             137.54 ±39.13      116.00 ±40.69      0.166
  HDL             46.15 ±10.52       38.3 ±12.99        0.094
  TC              210.23 ±47.50      184.73 ±43.95      0.152
  DM              4 (30.8%)          4 (26.7%)          0.811
  HL              9 (69.2%)          1 (6.7%)           0.001
  CAD             8 (61.5%)          12 (80.0%)         0.410
  PAH             2 (15.4%)          1 (6.7%)           0.583
  Renal atrophy   5 (38.5%)          1 (6.7%)           0.069
  CRF             13 (100%)          3 (20.0%)          \< 0.001

IeGFR -- improved glomerular filtration rate, DeGFR -- decreased glomerular filtration rate, Pre-DN -- preprocedural drug number used, Post-DN -- postprocedural drug number used, SP -- systolic blood pressure, DP -- diastolic blood pressure, EF -- left ventricle ejection fraction, WBC -- white blood cell count, HB -- hemoglobin, eGFR -- estimated glomerular filtration rate, LDL -- low-density lipoprotein, HDL -- high-density lipoprotein, TC -- total cholesterol, DM -- diabetes mellitus, HL -- hyperlipidemia, CAD -- coronary artery disease, PAH -- peripheral artery disease, CRF -- chronic renal failure

Discussion {#S0011}
==========

We found that blood pressure was significantly improved and medication needed to control blood pressure was significantly decreased after PTRAS. Although renal functions including eGFR and creatinine levels were not significantly affected by PTRAS, 46.4% of patients showed improvement of eGFR. Among patients with improved eGFR, baseline creatinine levels were significantly higher while basal eGFR levels were significantly lower. Presence of chronic renal failure was more common in these patients too. Data gathered from this subgroup suggested that patients with chronic renal failure had the most advantageous clinical outcomes from PTRAS. Both genders were shown to be equally affected by PTRAS.

Renal artery stenosis is an important cause of renovascular hypertension and renal insufficiency \[[@CIT0009]\]. Cardiovascular mortality and morbidity are increased in patients with atherosclerotic RAS that affects both genders \[[@CIT0010], [@CIT0011]\]. In accordance with the literature, the numbers of male and female patients were approximately equal in our study. Atherosclerotic RAS usually affects the renal artery ostium, thus complicating this procedure. Although PTRAS is effective in the treatment of RAS, optimal management of RAS is still controversial. The European Society of Cardiology guidelines on the diagnosis and treatment of peripheral arterial disease suggested PTRAS as a class 2B indication in patients with symptomatic severe ARAS (\> 60% renal artery stenosis) or impaired renal functions or recurrent unexplained congestive heart failure or pulmonary edema with preserved ejection fraction \[[@CIT0012]\]. Studies showed that the percutaneous procedure had little advantage or no clear effect on progression of impaired renal function \[[@CIT0003], [@CIT0004], [@CIT0013]\]. However, contrary to the literature, critical stenosis is accepted as \> 50% luminal narrowing in these studies. Furthermore, the procedural success rates were lower and complication rates were higher in these studies too. In contrast to these studies, critical stenosis was defined as luminal narrowing \> 70% in our study and we achieved a 100% angiographic success rate without major complications. Zeller *et al*. \[[@CIT0014]\] studied the long-term impact of stent-supported angioplasty on renal function and blood pressure control in 456 hemodynamically significant de novo RAS cases. They found that stent-supported angioplasty of RAS preserves renal function and improves blood pressure control in a broader spectrum of patients. Also, Lederman *et al*. \[[@CIT0015]\] studied the technical and clinical success of renal artery stenting in 300 consecutive patients with hypertension or renal insufficiency. They showed that 70% of patients had improved blood pressure control regardless of renal function after a median follow-up of 16 months. Similar to these findings, we observed that patients substantially benefited from the PTRAS procedure.

Measuring serum creatinine is a useful and sensitive marker of evaluating renal dysfunction. Creatinine is a non-protein waste product of creatine phosphate metabolism by skeletal muscle. Its production is continuous and is proportional to muscle mass. Creatinine is freely filtered and therefore the serum creatinine level depends on the GFR. Previous studies have shown serum creatinine levels significantly decreased after PTRAS and the decrease in serum creatinine levels tends to be larger in patients with higher serum creatinine levels \[[@CIT0014]\]. Although a significant decrease of mean serum creatinine levels was not observed in our study, we found that 46.4% of patients had improvement of eGFR after PTRAS and among these patients the baseline eGFR rate was significantly lower. This finding may be associated with correction of decreased blood flow in the ischemic renal area \[[@CIT0016]\]. Moreover, patients with chronic renal failure had a limited number of functioning nephrons and decreased blood flow further deteriorates the glomerular filtration. Correction of blood flow may provide enough perfusion pressure, and thus improvement of renal functions.

This study has several limitations. Blood pressure recordings were performed in outpatient clinic settings. Measurement of ambulatory blood pressure may supply beneficial information. The follow-up period was relatively short. The atheroembolization may deteriorate renal function during PTRAS \[[@CIT0017], [@CIT0018]\], but unfortunately we did not perform the procedure under distal protection. Renal artery stenosis is determined anatomically by angiographic appearance in this study. Doppler flow studies may give additional information regarding the severity of stenosis but unfortunately a Doppler flow study was not performed in this study. Another limitation of our study was the relatively small patient population; thus large scale studies with prolonged follow-up are further required to confirm our findings.

Conclusions {#S0012}
===========

Our results suggest that renal artery stenting is a safe procedure and may offer blood pressure control but beneficial effects of PTRAS on renal function may be anticipated in a selected group of patients, especially those with a low eGFR and bilateral RAS.
